CA2651755A1 - Methods and compositions for the diagnosis and treatment of cancer - Google Patents

Methods and compositions for the diagnosis and treatment of cancer Download PDF

Info

Publication number
CA2651755A1
CA2651755A1 CA002651755A CA2651755A CA2651755A1 CA 2651755 A1 CA2651755 A1 CA 2651755A1 CA 002651755 A CA002651755 A CA 002651755A CA 2651755 A CA2651755 A CA 2651755A CA 2651755 A1 CA2651755 A1 CA 2651755A1
Authority
CA
Canada
Prior art keywords
fgfr2
antibody
gene
antagonist
colorectal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651755A
Other languages
English (en)
French (fr)
Inventor
John Chant
Anthony S. Guerrero
Peter Haverty
Cynthia Honchell
Kenneth Jung
Thomas Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651755A1 publication Critical patent/CA2651755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002651755A 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer Abandoned CA2651755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79977206P 2006-05-12 2006-05-12
US60/799,772 2006-05-12
PCT/US2007/068737 WO2007134210A2 (en) 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
CA2651755A1 true CA2651755A1 (en) 2007-11-22

Family

ID=38694721

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651755A Abandoned CA2651755A1 (en) 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer

Country Status (5)

Country Link
US (2) US8945572B2 (https=)
EP (1) EP2018442A2 (https=)
JP (1) JP2009536834A (https=)
CA (1) CA2651755A1 (https=)
WO (1) WO2007134210A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2651755A1 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
PL2365828T3 (pl) 2008-11-07 2015-04-30 Galaxy Biotech Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
US20100136560A1 (en) * 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
US20120301482A1 (en) * 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
US20140141996A1 (en) * 2011-06-22 2014-05-22 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Cancer
JP2015505818A (ja) 2011-11-14 2015-02-26 ファイブ プライム セラピューティックス インコーポレイテッド 癌を治療する方法
AU2012351685A1 (en) * 2011-12-14 2014-07-03 Seattle Genetics, Inc. FGFR antibody drug conjugates (ADCs) and the use thereof
JPWO2014007369A1 (ja) * 2012-07-05 2016-06-02 国立研究開発法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US20170145103A1 (en) * 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US6900053B2 (en) 2001-09-14 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 2 expression
JP2002505431A (ja) * 1998-02-25 2002-02-19 アメリカ合衆国 迅速な分子プロファイリングのための細胞アッセイ法
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
IL128380A0 (en) * 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2001275337A1 (en) * 2000-06-07 2001-12-17 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7537905B2 (en) * 2003-01-15 2009-05-26 The Regents Of The University Of California Amplified and overexpressed gene in colorectal cancers
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
EP1871911A2 (en) * 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
CA2651755A1 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer

Also Published As

Publication number Publication date
WO2007134210A8 (en) 2009-07-30
US20150167101A1 (en) 2015-06-18
EP2018442A2 (en) 2009-01-28
WO2007134210A2 (en) 2007-11-22
US20090311250A1 (en) 2009-12-17
JP2009536834A (ja) 2009-10-22
US8945572B2 (en) 2015-02-03
WO2007134210A3 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
US8945572B2 (en) Methods and compositions for the diagnosis and treatment of cancer
AU2007319214B2 (en) Genetic variations associated with tumors
US20090324595A1 (en) Cancer prognostic diagnostic and treatment methods
JP5596975B2 (ja) 腫瘍と関連している遺伝的変異
US20150376289A1 (en) Methods and compositions for the diagnosis and treatment of cancer
EP2041320B1 (en) Methods and compositions for the diagnosis and treatment of cancer
HK1108924B (en) Cancer prognostic methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20160126